After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
Chengdu Kanghong's KH815 enters human testing this month.
